Ocera Therapeutics Inc (OCRX) : Vhcp Management Ii scooped up 140,000 additional shares in Ocera Therapeutics Inc during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Nov 14, 2016. The investment management firm now holds a total of 1,088,372 shares of Ocera Therapeutics Inc which is valued at $2,666,511.Ocera Therapeutics Inc makes up approximately 1.12% of Vhcp Management Ii’s portfolio.
Other Hedge Funds, Including , Geode Capital Management boosted its stake in OCRX in the latest quarter, The investment management firm added 90 additional shares and now holds a total of 60,728 shares of Ocera Therapeutics Inc which is valued at $148,784.Blackrock Investment Management boosted its stake in OCRX in the latest quarter, The investment management firm added 378 additional shares and now holds a total of 2,764 shares of Ocera Therapeutics Inc which is valued at $5,804.Blackrock Fund Advisors boosted its stake in OCRX in the latest quarter, The investment management firm added 7,614 additional shares and now holds a total of 53,850 shares of Ocera Therapeutics Inc which is valued at $113,085.Tower Research Capital (trc) reduced its stake in OCRX by selling 168 shares or 32.88% in the most recent quarter. The Hedge Fund company now holds 343 shares of OCRX which is valued at $720.
Ocera Therapeutics Inc closed down -0.2 points or -8.70% at $2.1 with 98,543 shares getting traded on Monday. Post opening the session at $2.3, the shares hit an intraday low of $2.1 and an intraday high of $2.325 and the price fluctuated in this range throughout the day.Shares ended Monday session in Red.
Many Wall Street Analysts have commented on Ocera Therapeutics Inc. Ocera Therapeutics Inc was Initiated by Aegis Capital to “Buy” on Nov 4, 2016.
Ocera Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is focused on acute and chronic orphan liver diseases. The Company is focused on the development and commercialization of a clinical candidate OCR-002 for the treatment of hepatic encephalopathy (HE). OCR-002 is a molecule ornithine phenylacetate which functions as an ammonia scavenger. In pre-clinical studies OCR-002 reduced arterial ammonia in an animal model of chronic liver disease and reduced arterial ammonia brain ammonia and intracranial pressure in a second animal model of acute liver failure. The Company has completed a Phase I pharmacokinetic and safety clinical trial of the intravenous form of OCR-002. A Phase IIa investigator-sponsored study in Spain tested OCR-002 in patients with upper gastrointestinal bleeding associated with liver cirrhosis. The Company is conducting a randomized placebo-controlled double blind Phase IIb clinical trial of OCR-002.